nach oben

Calcified Tissue International

Erschienen in:

01.10.2014 | Review

Effect of Clodronate Treatment on Risk of Fracture: A Systematic Review and Meta-analysis

verfasst von: B. Frediani, E. Baraldi, G. Cremonesi

Erschienen in: Calcified Tissue International | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

A systematic review and a meta-analysis of data of literature were performed to evaluate the efficacy of clodronate in the reduction of risk of fractures in patients with osteoporosis or tumour diseases. A systematic review was conducted to identify original articles, reviews, and any other literature report suitable for the purposes of the meta-analysis, limited to prospective randomized trials that included a placebo or an untreated control arm. The search has identified 18 trials, 13 of which in patients with cancer diseases (breast cancer and multiple myeloma were prevalent), 4 in patients with osteoporosis/low BMD, and 1 in elderly women living in community. A placebo control arm was used in 13 trials. Treatment and follow-up duration ranged from 3 months to 5 years. The meta-analysis showed that treatment with clodronate was associated with a reduction of the probability of new fractures compared with controls (OR = 0.572, 95 % CI 0.465–0.704 for new vertebral fractures; OR = 0.668, 95 % CI 0.494–0.905 for new non-vertebral fractures; and OR = 0.744, 95 % CI 0.635–0.873 for new overall fractures in those articles where vertebral and non-vertebral new fractures were not considered separately). Similar findings were observed in the separate analysis in patients with cancer forms or osteoporosis. The results of the meta-analysis have demonstrated that clodronate is effective in reducing the risk of vertebral, non-vertebral, and overall fractures in patients with skeletal fragility.

Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285(3):320–323PubMedCrossRef

Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721–739PubMedCrossRef

Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11(7):556–561PubMedCrossRef

Morin S, Lix LM, Azimaee M, Metge C, Caetano P, Leslie WD (2011) Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int 22(9):2439–2448PubMedCrossRef

Rostom S, Allali F, Bennani L, Abouqal R, Hajjaj-Hassouni N (2012) The prevalence of vertebral fractures and health-related quality of life in postmenopausal women. Rheumatol Int 32(4):971–980PubMedCrossRef

Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di Matteo L, Scendoni P, Grassi W, Italian Multicentre Osteoporotic Fracture Study Group (2007) The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 34(7):1551–1560PubMed

Lustberg MB, Reinbolt RE, Shapiro CL (2012) Bone health in adult cancer survivorship. J Clin Oncol 30(30):3665–3674PubMedCrossRef

Roodman GD (2004) Mechanisms of bonemetastasis. N Engl J Med 350(16):1655–1664PubMedCrossRef

Winter MC, Coleman RE (2013) Bisphosphonates in the adjuvant treatment of breast cancer. Clin Oncol (R Coll Radiol) 25(2):135–145CrossRef

10.

Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593PubMedCrossRef

11.

Kawatani M, Osada H (2009) Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases. Cancer Sci 100(11):1999–2005PubMedCrossRef

12.

Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev, CD003474

13.

Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16(2):593–602PubMed

14.

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377–387PubMed

15.

Ghinoi V, Brandi ML (2002) Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders. Expert Opin Pharmacother 3(11):1643–1656PubMedCrossRef

16.

Frediani B, Cavalieri L, Cremonesi G (2009) Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig 29(6):359–379PubMedCrossRef

17.

Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ (2001) The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44(9):2201–2210PubMedCrossRef

18.

Filipponi P, Cristallini S, Rizzello E, Policani G, Fedeli L, Gregorio F, Boldrini S, Troiani S, Massoni C (1996) Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone 18(2):179–184PubMedCrossRef

19.

McCloskey E, Selby P, de Takats D, Bernard J, Davies M, Robinson J, Francis R, Adams J, Pande K, Beneton M, Jalava T, Löyttyniemi E, Kanis JA (2001) Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone 28(3):310–315PubMedCrossRef

20.

McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19(5):728–736PubMedCrossRef

21.

Elomaa I, Blomqvist C, Porkka L, Holmström T, Taube T, Lamberg-Allardt C, Borgström GH (1988) Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother 42(2):111–116PubMed

22.

Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgström GH (1987) Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 8(Suppl 1):S53–S56PubMed

23.

McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT (2001) Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113(4):1035–1043PubMedCrossRef

24.

McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100(2):317–325PubMedCrossRef

25.

Delmas PD, Charhon S, Chapuy MC, Vignon E, Briancon D, Edouard C, Meunier PJ (1982) Long-term effects of dichloromethylenediphosphonate (CI2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Relat Res 4(3):163–168PubMedCrossRef

26.

Merlini G, Parrinello GA, Piccinini L, Crema F, Fiorentini ML, Riccardi A, Pavesi F, Novazzi F, Silingardi V, Ascari E (1990) Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 8(1):23–30PubMedCrossRef

27.

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B (2012) Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev, 5:CD003188. doi:10.1002/14651858.CD003188.pub3

28.

Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49(1):2–19PubMedCrossRef

29.

Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP (2010) Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 16(27):2950–2960PubMedCrossRef

30.

Berenson JR (2011) Antitumor effects of bisphosphonates: from the laboratory to the clinic. Curr Opin Support Palliat Care 5(3):233–240PubMedCrossRef

31.

Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19(1):420–432PubMed

32.

Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghé F, Pannuti F (1991) Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 48(2):97–101PubMedCrossRef

33.

Tanakol R, Yarman S, Bayraktaroglu T, Boztepe H, Alagöl F (2007) Clodronic acid in the treatment of postmenopausal osteoporosis. Clin Drug Investig 27(6):419–433PubMedCrossRef

34.

Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 340(8827):1049–1052PubMedCrossRef

35.

Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E (2001) Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88(7):701–707PubMed

36.

Beard MK (2012) Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference. Curr Med Res Opin 28(1):141–147PubMedCrossRef

37.

Lee S, Glendenning P, Inderjeeth CA (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 22(3):741–753PubMedCrossRef

38.

Frediani B, Falsetti P, Baldi F, Acciai C, Filippou G, Marcolongo R (2003) Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone 33(4):575–581PubMedCrossRef

39.

Tauchmanova L, Guerra E, Pivonello R, De Martino MC, De Leo M, Caggiano F, Lombardi G, Colao A (2009) Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing’s syndrome. J Endocrinol Invest 32(5):390–394PubMedCrossRef

40.

Jansen JP, Bergman GJ, Huels J, Olson M (2011) The efficacy of bisphosphonates in the prevention of vertebral, hip, and non vertebral-non hip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 40(4):275–284PubMedCrossRef

41.

Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24(1):237–245PubMedCrossRef

42.

Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97(6):1871–1880PubMedCrossRef

43.

Reginster JY (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71(1):65–78PubMedCrossRef

44.

Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11(1):59–65PubMed

45.

Clemens MR, Fessele K, Heim ME (1993) Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 66(3):141–146PubMedCrossRef

46.

Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S (1996) Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19(6):663–667PubMedCrossRef

47.

Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246(1):67–74PubMedCrossRef

48.

Saarto T, Blomqvist C, Virkkunen P, Elomaa I (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19(1):10–17PubMed

49.

Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK, Mrc Pr05 Collaborators (2003) A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 95(17):1300–1311PubMedCrossRef

50.

Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8(2):R13PubMedCrossRefPubMedCentral

51.

McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, Orgee J, Ashford R, Forster M, Cliffe J, Kersh L, Brazier J, Nichol J, Aropuu S, Jalava T, Kanis JA (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22(1):135–141PubMedCrossRef

Titel: Effect of Clodronate Treatment on Risk of Fracture: A Systematic Review and Meta-analysis
verfasst von: B. Frediani
E. Baraldi
G. Cremonesi
Publikationsdatum: 01.10.2014
Verlag: Springer US
Erschienen in: Calcified Tissue International / Ausgabe 4/2014
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-014-9903-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Comment on Osteocytes: Masters Orchestrators of Bone

Effects on Calcium Homeostasis of Changing PTH Replacement Therapy of Postoperative Hypoparathyroidism from Intact PTH to Teriparatide: A Case Series

Glucocorticoid-Induced Osteoporosis in Growing Rats

Authors Response to Letter from Plotkin and Bellido

Osteoporosis and the Risk of Symptomatic Nephrolithiasis: A Population-Based 5-Year Follow-Up Study in Taiwan